Group One Trading’s AbbVie ABBV Stock Holding History

Group One Trading’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.5M	Sell	149,300 -11,000	-7%	-$2.44M	0.06%	305
2025 Q4	$36.6M	Buy	160,300 +80,800	+102%	+$18.4M	0.06%	299
2025 Q3	$18.4M	Sell	79,500 -40,900	-34%	-$8.33M	0.03%	537
2025 Q2	$22.3M	Sell	120,400 -36,100	-23%	-$6.71M	0.05%	379
2025 Q1	$32.8M	Buy	156,500 +43,700	+39%	+$8.5M	0.1%	177
2024 Q4	$20M	Buy	112,800 +51,000	+83%	+$9.38M	0.05%	380
2024 Q3	$12.2M	Buy	61,800 +22,100	+56%	+$4.12M	0.03%	504
2024 Q2	$6.81M	Sell	39,700 -20,400	-34%	-$3.38M	0.03%	631
2024 Q1	$10.9M	Sell	60,100 -46,200	-43%	-$7.96M	0.04%	405
2023 Q4	$16.5M	Buy	106,300 +48,800	+85%	+$7.11M	0.04%	442
2023 Q3	$8.57M	Sell	57,500 -2,700	-4%	-$396K	0.03%	606
2023 Q2	$8.11M	Sell	60,200 -19,900	-25%	-$2.92M	0.03%	628
2023 Q1	$12.8M	Sell	80,100 -458,100	-85%	-$70M	0.05%	360
2022 Q4	$87M	Buy	538,200 +82,800	+18%	+$12.7M	0.2%	75
2022 Q3	$61.1M	Buy	455,400 +16,700	+4%	+$2.4M	0.12%	112
2022 Q2	$67.2M	Sell	438,700 -470,500	-52%	-$71.9M	0.11%	131
2022 Q1	$147M	Buy	909,200 +184,300	+25%	+$26.8M	0.15%	73
2021 Q4	$98.2M	Buy	724,900 +376,000	+108%	+$44.4M	0.08%	151
2021 Q3	$37.6M	Sell	348,900 -89,500	-20%	-$10.2M	0.04%	369
2021 Q2	$49.4M	Buy	438,400 +213,100	+95%	+$24M	0.06%	255
2021 Q1	$24.4M	Sell	225,300 -534,900	-70%	-$57.2M	0.04%	445
2020 Q4	$81.5M	Buy	760,200 +164,900	+28%	+$15.8M	0.14%	91
2020 Q3	$52.1M	Sell	595,300 -96,400	-14%	-$9.08M	0.16%	94
2020 Q2	$67.9M	Buy	691,700 +53,100	+8%	+$4.68M	0.31%	34
2020 Q1	$48.7M	Buy	638,600 +144,900	+29%	+$12.3M	0.39%	33
2019 Q4	$43.7M	Buy	493,700 +176,600	+56%	+$14.7M	0.3%	42
2019 Q3	$24M	Sell	317,100 -111,700	-26%	-$7.66M	0.19%	85
2019 Q2	$31.2M	Buy	428,800 +254,600	+146%	+$20M	0.28%	42
2019 Q1	$14M	Sell	174,200 -88,000	-34%	-$7.2M	0.16%	113
2018 Q4	$24.2M	Buy	262,200 +19,500	+8%	+$1.71M	0.21%	82
2018 Q3	$23M	Sell	242,700 -4,200	-2%	-$398K	0.18%	102
2018 Q2	$22.9M	Buy	246,900 +6,600	+3%	+$645K	0.2%	81
2018 Q1	$22.7M	Sell	240,300 -363,900	-60%	-$40M	0.23%	74
2017 Q4	$58.4M	Buy	604,200 +96,800	+19%	+$9.12M	0.41%	25
2017 Q3	$45.1M	Buy	507,400 +146,800	+41%	+$11.2M	0.41%	25
2017 Q2	$26.1M	Buy	360,600 +195,400	+118%	+$13.1M	0.27%	59
2017 Q1	$10.8M	Sell	165,200 -177,400	-52%	-$11.2M	0.13%	175
2016 Q4	$21.5M	Sell	342,600 -67,000	-16%	-$4.09M	0.21%	93
2016 Q3	$25.8M	Sell	409,600 -245,200	-37%	-$15.9M	0.28%	61
2016 Q2	$40.5M	Buy	654,800 +128,700	+24%	+$7.84M	0.48%	22
2016 Q1	$30.1M	Sell	526,100 -423,100	-45%	-$23.6M	0.42%	24
2015 Q4	$56.2M	Buy	949,200 +126,500	+15%	+$7.29M	0.66%	8
2015 Q3	$44.8M	Sell	822,700 -225,500	-22%	-$14.7M	0.62%	10
2015 Q2	$70.4M	Buy	1,048,200 +283,400	+37%	+$18.5M	0.99%	3
2015 Q1	$44.8M	Buy	764,800 +287,400	+60%	+$17.4M	0.7%	11
2014 Q4	$31.2M	Buy	477,400 +213,200	+81%	+$13.4M	0.47%	27
2014 Q3	$15.3M	Buy	264,200 +154,700	+141%	+$8.59M	0.24%	60
2014 Q2	$6.18M	Buy	109,500 +62,100	+131%	+$3.26M	0.1%	230
2014 Q1	$2.44M	Sell	47,400 -197,400	-81%	-$9.98M	0.04%	527
2013 Q4	$12.9M	Buy	244,800 +58,100	+31%	+$2.86M	0.2%	71
2013 Q3	$8.35M	Buy	186,700 +43,600	+30%	+$1.93M	0.16%	102
2013 Q2	$5.92M	Buy	+143,100	New	+$6.26M	0.15%	133

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Group One Trading's ABBV Position: Q3 2024 in Review

Group One Trading sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 15,610 shares — an estimated $2.91M sold.

Group One Trading first reported a position in ABBV in Q2 2013 and held it in 23 quarters. The position peaked at $23M in Q1 2015. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Group One Trading reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
Group One Trading sold 15,610 AbbVie shares in Q3 2024, an estimated $2.91M.
Group One Trading first reported a position in AbbVie in Q2 2013 and held it in 23 quarters.
Group One Trading's AbbVie position peaked at $23M in Q1 2015.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Group One Trading's 13F filing for Q3 2024, filed 14 Nov 2024.